Cardiovascular Disease (CVD)

Venous Thromboembolism Risk in Lupus Nephritis Not Limited to Class 5

Publish Date March 5, 2021

This the first study to evaluate the risk for venous thromboembolism by lupus nephritis class, according to investigators.

BPH Medications May Increase Heart Failure Risk

Publish Date March 4, 2021

It is important for urologists and primary care physicians to be aware of the potential link between BPH medications and heart failure risk, according to investigators.

Exercise Doppler Echocardiography Found to Consistently Assess Right Heart, Pulmonary Circulation

Publish Date March 4, 2021

Exercise Doppler echocardiography may provide consistent assessment of right heart function and pulmonary circulation when conducted at expert centers.

KDIGO Updates Blood Pressure Guideline for Nondialysis CKD

Publish Date March 2, 2021

The new KDIGO guideline recommendation to target a systolic blood pressure of less than 120 mm Hg in many patients with nondialysis CKD is lower than the 2012 target recommended in 2012.

Entresto Approval Expands Use to More HF Patients With LVEF Below Normal

Publish Date February 26, 2021

The approval was based on data from the double-blind, parallel-group, active-controlled phase 3 PARAGON-HF trial.

Healthy Lifestyle May Lower Death, MACE Risk in Chronic Kidney Disease

Publish Date February 26, 2021

Study findings show that the survival and cardiovascular benefits of a healthy lifestyle extend to individuals with reduced kidney function who are at higher risk for cardiovascular disease.

Cardiovascular Risk Factors Undertreated in Veterans With Prostate Cancer

Publish Date February 25, 2021

In a study, 1 in 4 male veterans with prostate cancer failed to receive a comprehensive assessment of their cardiovascular risk factors.

Strict Phosphate Control May Slow Coronary Artery Calcification in HD

Publish Date February 25, 2021

Vascular calcification is the most likely mechanism underlying the association between hyperphosphatemia and mortality, according to investigators.

Comparable Efficacy of Rivaroxaban Plus Aspirin Regimen Across BMI, Body Weight Categories

Publish Date February 24, 2021

Rivaroxaban plus aspirin regimen for chronic atherosclerotic vascular disease may not require adjustment based on BMI or weight.

Guideline-Directed Pharmacotherapies for HFrEF and Survival Outcomes in Patients With Comorbid Low BP and Renal Dysfunction

Publish Date February 5, 2021

Patients with HFrEF who have low systolic blood pressure and renal dysfunction were found to have better survival outcomes when treated with all 3 guideline-directed pharmacotherapies.